角质形成细胞生长因子治疗急性呼吸窘迫综合征(KARE):一项随机双盲安慰剂对照2期试验
KGF组无呼吸机天数更少、通气时间更长、28天死亡率更高、不良事件更多。
要点
- KGF未改善ARDS患者第7天氧合指数。
- KGF组无呼吸机天数更少、存活者通气时间更长。
- KGF组28天死亡率更高、不良事件更多,可能有害。
核心结论
- KGF未改善ARDS的生理或临床结局,且可能对患者健康有害。
研究设计与样本
- 双盲、分配隐藏、随机、安慰剂对照2期试验,在英国两个ICU进行,纳入符合欧美共识会议ARDS定义的患者。
- 共招募60例患者,KGF组29例、安慰剂组31例,全部纳入主要结局分析,分析采用意向性治疗。
临床怎么用
- 不推荐对ARDS患者使用角质形成细胞生长因子(帕利夫明)治疗。
- 该结果提示KGF可能增加死亡和不良事件风险,应避免在此类患者中应用。
局限性
- 原文未报告局限性说明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data from in-vitro, animal, and human lung injury models suggest that keratinocyte growth factor (KGF) might be beneficial in acute respiratory distress syndrome (ARDS). The objective of this trial was to investigate the effect of KGF in patients with ARDS. METHODS: We did a double-blind, allocation concealed, randomised, placebo-controlled phase 2 trial in two intensive care units in the UK, involving patients fulfilling the American-European Consensus Conference Definition of ARDS. Patients were randomly assigned (1:1) by computer-generated randomisation schedule with variable block size stratified by site and presence of severe sepsis requiring vasopressors to receive either recombinant human KGF (palifermin 60 μg/kg) or placebo (0·9% sodium chloride solution) daily for a maximum of 6 days. Both patients and investigators were masked to treatment. The primary endpoint was oxygenation index (OI) at day 7. Analyses were by intention to treat. The trial is registered with International Standard Randomised Controlled Trial Registry, number ISRCTN95690673. FINDINGS: Between Feb 23, 2011, and Feb 26, 2014, 368 patients were assessed for eligibility for inclusion in the trial. Of the 60 patients recruited, 29 patients were randomly assigned to receive KGF and 31 to placebo; all were included in the analysis of the primary outcome. There was no significant difference between the two groups in OI at day 7 (mean 62·3 [SD 57·8] in the KGF group, 43·1 [33·5] in the placebo group; mean difference 19·2, 95% CI -5·6 to 44·0, p=0·13). Of interest, although not defined as outcome measures a priori, the KGF group, compared with placebo, had fewer median ventilator-free days (1 day [IQR 0 to 17] in the KGF group vs 20 days [13-22] in the placebo group; difference -8 days, 95% CI -17 to -2; p=0·0002), a longer median duration of ventilation in survivors to day 90 (16 days [IQR 13-30] in the KGF group vs 11 days [8-16] in the placebo group; difference 6 days, 95% CI 2 to 14; p=0·002), and a higher mortality at 28 days (nine [31%] vs three [10%] deaths; risk ratio 3·2, 95% CI 1·0 to 10·7, p=0·054). Adverse events were more frequent in the KGF group than the placebo group (14 vs 5 events; odds ratio 4·9, 95% CI 1·3 to 20·3, p=0·008). The two adverse events assessed as related to KGF were due to pyrexia. INTERPRETATION: KGF did not improve physiological or clinical outcomes in ARDS and might be harmful to patient health. FUNDING: The Northern Ireland Public Health Agency Research and Development Division.
引用
- McAuley DF, Cross LM, Hamid U, et al. Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Respir Med. 2017. PMID: 28526233. doi:10.1016/S2213-2600(17)30171-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。